Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs)
EXCLI Journal · 04.06.2024 · 23 · 862-882
DOI: 10.17179/excli2024-7076 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 04.06.2024. Verfasst von Ali Hassanzadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Zitieren
APA
Hassanzadeh, A., Shomali, N., Kamrani, A., Soltani-Zangbar, M. S., Nasiri, H., & Akbari, M. (2024). Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs). EXCLI Journal, 23, 862-882. https://doi.org/10.17179/excli2024-7076
Vancouver
Hassanzadeh A, Shomali N, Kamrani A, Soltani-Zangbar MS, Nasiri H, Akbari M. Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs). EXCLI Journal. 2024;23:862-882. doi:10.17179/excli2024-7076
BibTeX
@article{Hassanzadeh2024,
author = {Hassanzadeh, Ali and Shomali, Navid and Kamrani, Amin and Soltani-Zangbar, Mohammad Sadegh and Nasiri, Hadi and Akbari, Morteza},
title = {Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs)},
journal = {EXCLI Journal},
year = {2024},
volume = {23},
pages = {862--882},
doi = {10.17179/excli2024-7076}
}
EUVIMED